TCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TScan Therapeutics Inc (TCRX) is not a strong buy for a beginner, long-term investor at this moment. The technical indicators show bearish trends, and the stock has a declining pre-market price. While hedge funds are buying, there is no significant insider activity or news catalysts. Financial performance shows improvement in revenue and net income, but the company is still operating at a loss. Given the lack of strong positive signals, it is better to hold off on investing in this stock right now.
The MACD is positive and expanding, suggesting slight bullish momentum. However, the RSI is neutral at 58.555, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The pre-market price is down -4.39%, trading below the pivot level of 0.984, with support at 0.913 and resistance at 1.055.
Hedge funds are significantly increasing their holdings, with a 12447.81% increase in buying over the last quarter. Financials show revenue growth of 139.37% YoY and a slight improvement in net income and EPS.
The stock is trading down -4.39% in the pre-market, and moving averages indicate a bearish trend. There is no recent news, no significant insider activity, and no recent congress trading data. The company is still operating at a net loss of -$35.71M.
In Q3 2025, revenue increased by 139.37% YoY to $2.51M. Net income improved by 19.48% YoY but remains negative at -$35.71M. EPS improved by 12% YoY to -0.28. Gross margin remains at 100%.
No recent analyst rating or price target changes available.
